Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium

DC Muller; TL Larose; A Hodge; F Guida; A Langhammer; K Grankvist; K Meyer; Q Cai; AA Arslan; A Zeleniuch-Jacquotte; D Albanes; GG Giles; HD Sesso; IM Lee; JM Gaziano; JM Yuan; JH Bolton; JE Buring; K Visvanathan; L Le Marchand; MP Purdue; NE Caporaso; Ø Midttun; PM Ueland; RL Prentice; SJ Weinstein; VL Stevens; W Zheng; WJ Blot; XO Shu; X Zhang; YB Xiang; WP Koh; K Hveem; CA Thomson; M Pettinger; G Engström; H Brunnström; RL Milne; MJ Stampfer; J Han; M Johansson; P Brennan; G Severi; M Johansson

Journal article

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: Nested case-control study within Lung Cancer Cohort Consortium

DC Muller, TL Larose, A Hodge, F Guida, A Langhammer, K Grankvist, K Meyer, Q Cai, AA Arslan, A Zeleniuch-Jacquotte, D Albanes, GG Giles, HD Sesso, IM Lee, JM Gaziano, JM Yuan, JH Bolton, JE Buring, K Visvanathan, L Le Marchand Show all

BMJ Online | BMJ PUBLISHING GROUP | Published : 2019

DOI: 10.1136/bmj.k4981

Abstract

Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. ParticiPants 5299 patients with incident lung cancer, with individually incidence density matched controls. exPOsure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main OutcOMe Measure Incident lung cancer diagnosis. results A positive association between circulating hsCRP concentrati..

View full abstract

University of Melbourne Researchers

Allison Hodge Author

Graham Giles Author

Roger Milne Author

Grants

Awarded by Norges Teknisk-Naturvitenskapelige Universitet

Funding Acknowledgements

The Lung Cancer Cohort Consortium was supported by Grant National Institutes of Health/National Cancer Institute (no 1U01CA155340-01) and The National Health and Medical Research Council (Grant ID: 1050198). DCM receives funding from a Cancer Research UK Population Research Fellowship. This work was supported by The Research Council of Norway (grant no 267776/H10). The work undertaken by TLL for this paper was conducted during a postdoctoral placement at the International Agency for Research on Cancer, within the framework of an agreement between the Research Council of Norway and the Norwegian University of Science and Technology. The funding organisations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript.